New insights into long non-coding RNAs in non-small cell lung cancer - 28/10/20
, Ruixiang Tang c, 1, Siyuan Gan a, b, 1, Rujia Li a, b, Ying Cheng a, b, Linlang Guo d, Chao Zeng e, ⁎ , Yanqin Sun a, b, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | Clinical application of LncRNAs to the diagnosis, prognosis, and therapy of NSCLC. |
• | Circulating lncRNAs has potential as a biomarker for early screening,diagnosis of NSCLC. |
• | LncRNAs function as oncogenes or tumor suppressors in NSCLC. |
• | LncRNAs are involved in the development of drug resistance in NSCLC. |
Abstract |
Lung cancer is a malignant tumor that seriously threatens human life and health. Non-small cell lung cancer (NSCLC) accounts for 85 % of all lung cancer cases, and its global 5-year survival rate is only approximately 5%. Thus, the identification of new prognostic biomarkers has become one of the most urgent challenges in NSCLC research. Long noncoding RNAs (LncRNAs) are a kind of noncoding RNA whose length exceeds 200 nucleotides (nt). LncRNAs are transcribed by RNA pol II and can be subjected to posttranscriptional modifications such as blocking, polyadenylation and splicing; moreover, their expression profiles are more specific than those of mRNAs. Emerging evidence confirms that lncRNAs are associated with the occurrence and development of NSCLC and play an important role in NSCLC drug resistance. The purpose of this review was to describe the roles of lncRNAs in the development, diagnosis and prognosis of NSCLC and to explore new evidence of lncRNAs in the treatment of NSCLC drug resistance. This review provides a new perspective of lncRNAs in the treatment of NSCLC.
Le texte complet de cet article est disponible en PDF.Abbreviation : NSCLC, SCLC, SCC, LAC, ADC, LncRNA, MiRNA, PiRNA, SiRNA, TsRNA, LincRNA, VlncRNA, CAR10, AFAP1-AS1, SBF2-AS1, SPRY4-IT1, LUCAT1, MEG3, TUG1, CASC2, PANDAR, SOX2ot, ANRIL, UCA1, XIST, GAS5, MALAT1, HOTAIR, CCAT1, BLACAT1, RHPN1-AS1, LOC285194, ENCODE, ORF, EZH2, PRC2, RISC, H3K27me3, EGFR, TKI, ALK, mTOR, PFS, OS, EMT, TNM, AUC, CEA, GEO, Bcl-2, LRP1, TRIM16, ABCG2, ATG7, MRP1, LSD1, qRT-PCR, CYFRA21-1, LATS2, ABCG2, ZFNs
Keywords : LncRNAs, NSCLC, Drug resistance
Plan
Vol 131
Article 110775- novembre 2020 Retour au numéro
Article précédent
- Norcantharidin: research advances in pharmaceutical activities and derivatives in recent years
- Jianbo Zhou, Yali Ren, Lu Tan, Xiaominting Song, Miao Wang, Yuzhi Li, Zhixing Cao, Chuanjie Guo
- Anxiety: An ignored aspect of Parkinson’s disease lacking attention
- Dharmendra Kumar Khatri, Mamta Choudhary, Anika Sood, Shashi Bala Singh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?